THE LATEST

NEWS & EVENTS

  • Sort By:
Mar 27, 2020

The COVID-19 Rheumatology Patient Experience Survey

Thank you again for supporting the COVID–19 Global Rheumatology Alliance! Today, we launched The COVID-19 Rheumatology Patient Experience Survey. This survey is for adult patients with a rheumatic illness or the parents of a child with a rheumatic illness. With this information, we hope to obtain insights about how best to prevent or treat COVID-19 as well as understand the challenges patients are facing in this uncertain time.

Mar 27, 2020

The COVID-19 Global Rheumatology Alliance: Provider-Entered Registry

Our mission is to create a secure, de-identified, international case reporting registry and curate and disseminate the outputs from that registry. It is our hope that the information collected will help guide rheumatology clinicians in assessing and treating patients with rheumatologic disease and in evaluating the risk of infection in patients on immunosuppression. We are asking that clinicians use this site to report any and all cases of COVID-19 in rheumatology patients, including those with mild or no symptoms. We anticipate that completion of the case report form will take 5-10 minutes and no protected health information is requested. We plan to use the relevant information from these cases to provide expeditious updates to the global rheumatology community. The success of this voluntary effort depends on our joint participation and the breadth of information collected. We ask that you share this site with your colleagues internationally and encourage reporting. We were inspired by our colleagues in the IBD community who have put forth the helpful https://covidibd.org/ registry and urge anyone with information about coronavirus cases in patients with IBD to use the case reporting form on that site. Thank you for your contribution to this important work. The COVID-19 Global Rheumatology Alliance Team

Mar 27, 2020

Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients with SLE that had a different primary end point. The frequency of herpes zoster was higher with anifrolumab than with placebo.

Dec 12, 2019

Dr. Rosalind Ramsey-Goldman Receives the ACR Master Designation

Congratulations to Dr. Rosalind Ramsey-Goldman on being a 2019 recipient of the ACR Master Designation. This honor is presented to ACR members how have demonstrated outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession.

Dec 12, 2019

Dr. Michelle Petri Receives ACR Master Designation

Dr. Michelle Petri has recieved the 2019 ACR Master Designation. Recognition as a Master of the American College of Rheumatology is one of the highest honors the College bestows. The honour is awarded to researchers who have made outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession.

Dec 12, 2019

Dr. Susan Manzi receives 2019 Distinguished Clinical Investigator Award

Congratulations to Dr. Susan Manzi on receiving the 2019 American College of Rheumatology, Distinguished Clinical Investigator Award. The Distinguished Clinical Investigator Award is awarded each year to a clinical scientist for making outstanding contributions to the field of rheumatology.

Next
1 of 5